Orchestra BioMed Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Orchestra BioMed Holdings şirketinin toplam hissedar öz sermayesi $46.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $75.3M ve $29.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$66.93m
Eşitlik	US$46.22m
Toplam yükümlülükler	US$29.10m
Toplam varlıklar	US$75.32m

Son finansal sağlık güncellemeleri

Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

Mar 01

Recent updates

Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

Mar 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OBIO 'nin kısa vadeli varlıkları ( $68.6M ) kısa vadeli yükümlülüklerini ( $16.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: OBIO şirketinin kısa vadeli varlıkları ( $68.6M ) uzun vadeli yükümlülüklerini ( $12.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OBIO borçsuzdur.

Borcun Azaltılması: OBIO un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: OBIO şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: OBIO serbest nakit akışı her yıl % 25.2 1.3 yıl yetecek nakit akışına sahip olacaktır.

Orchestra BioMed Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

Recent updates

Orchestra BioMed Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Orchestra BioMed Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Orchestra BioMed Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Orchestra BioMed Holdings, Inc. Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Orchestra BioMed Holdings, Inc., Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Orchestra BioMed Holdings, Inc. Announces Appointment of David Pacitti to Board of Directors

Orchestra Biomed Holdings, Inc. Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

Orchestra Biomed Holdings, Inc. Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy in Hypertensive Pacemaker Patients

Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

Orchestra Biomed Announces Initiation of Backbeat Pivotal Study of Avim Therapy in Hypertensive Pacemaker Patients

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Orchestra Biomed Holdings, Inc. Receives Fda Approval of Ide for U.S. Pivotal Study of Virtue(R) Sirolimus Angioinfusion Balloon in Patients with Coronary In-Stent Restenosis

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy

Full year 2022 earnings released: US$14.60 loss per share (vs US$10.90 loss in FY 2021)

Orchestra BioMed Holdings, Inc. Announces Management Changes

Orchestra BioMed, Inc. completed the acquisition of Health Sciences Acquisitions Corporation 2 (NasdaqCM:HSAQ) from HSAC 2 Holdings, LLC, RTW Investments, LP and others in a reverse merger transaction.

No independent directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin